For instance, flecainide prevents arrhythmias in a mouse model of Catecholaminergic Polymorphic Ventricular Tachycardia (CPVT) by inhibiting cardiac RYR2–mediated Ca2+ release [43, 64, 65] and is now considered a valid therapeutic approach in CPVT patients non-responsive to betablockade alone. Here, RYR2 is linked to catecholaminergic polymorphic ventricular tachycardia.